Thomas J. Schall

Q: What Schools Are Affiliated With Thomas J. Schall

Thomas J. Schall is affiliated with the following schools: University of Oxford, McMaster University, Kiel University, Stanford University, RWTH Aachen University, Université Laval

Thomas J. Schall's AcademicInfluence.com Rankings

Thomas J. Schall

Philosophy

#6536

World Rank

#9585

Historical Rank

Logic

#3689

World Rank

#4885

Historical Rank

philosophy Degrees

Thomas J. Schall

Biology

#8870

World Rank

#12007

Historical Rank

Virology

#199

World Rank

#205

Historical Rank

Immunology

#519

World Rank

#536

Historical Rank

Biochemistry

#1310

World Rank

#1430

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Thomas J. Schall's Degrees

PhD Biochemistry Stanford University
Doctorate Medicine Harvard University

Why Is Thomas J. Schall Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Thomas J. Schall's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Identification of a major co-receptor for primary isolates of HIV-1 (1996) (3874)
A new class of membrane-bound chemokine with a CX3C motif (1997) (2019)
Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES (1990) (1458)
Identification and Molecular Characterization of Fractalkine Receptor CX3CR1, which Mediates Both Leukocyte Migration and Adhesion (1997) (1409)
A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development (2006) (1271)
Molecular cloning and expression of a receptor for human tumor necrosis factor (1990) (955)
Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor (1993) (820)
Chemokine receptors: Gateways to inflammation and infection (1996) (721)
Chemokines, leukocyte trafficking, and inflammation. (1994) (702)
Biology of the RANTES/SIS cytokine family. (1991) (694)
Lymphotactin: a cytokine that represents a new class of chemokine. (1994) (690)
RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes (1992) (641)
CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature (2007) (557)
Activation of dual T cell signaling pathways by the chemokine RANTES. (1995) (509)
Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes (1993) (503)
A human T cell-specific molecule is a member of a new gene family. (1988) (496)
CCR6, a CC Chemokine Receptor that Interacts with Macrophage Inflammatory Protein 3α and Is Highly Expressed in Human Dendritic Cells (1997) (391)
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. (2017) (364)
The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. (2010) (359)
Regulation of the production of the RANTES chemokine by endothelial cells. Synergistic induction by IFN-gamma plus TNF-alpha and inhibition by IL-4 and IL-13. (1995) (354)
Chemokine/chemokine receptor nomenclature. (2003) (352)
Cytomegalovirus encodes a potent alpha chemokine. (1999) (350)
Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts. Differential regulation of RANTES and interleukin-8 genes by inflammatory cytokines. (1993) (316)
Overcoming hurdles in developing successful drugs targeting chemokine receptors (2011) (306)
Potent Immunosuppressive Activities of Cytomegalovirus- Encoded Interleukin-10 (2002) (305)
Elucidation of CXCR7-Mediated Signaling Events and Inhibition of CXCR4-Mediated Tumor Cell Transendothelial Migration by CXCR7 Ligands (2009) (285)
Cytokine expression by neutrophils and macrophages in vivo: endotoxin induces tumor necrosis factor-alpha, macrophage inflammatory protein-2, interleukin-1 beta, and interleukin-6 but not RANTES or transforming growth factor-beta 1 mRNA expression in acute lung inflammation. (1994) (283)
Identification of a promiscuous inflammatory peptide receptor on the surface of red blood cells. (1993) (279)
Expression of the chemokine RANTES by a human bronchial epithelial cell line. Modulation by cytokines and glucocorticoids. (1995) (274)
C5a receptor (CD88) blockade protects against MPO-ANCA GN. (2014) (244)
Peritoneal fluid concentrations of the cytokine RANTES correlate with the severity of endometriosis. (1993) (242)
Cutting Edge: Identification of a Novel Chemokine Receptor That Binds Dendritic Cell- and T Cell-Active Chemokines Including ELC, SLC, and TECK (2000) (225)
Molecular cloning and functional characterization of human lymphotactin. (1995) (221)
The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. (2015) (205)
C-C chemokines induce the chemotaxis of NK and IL-2-activated NK cells. Role for G proteins. (1994) (204)
Neuronal Fractalkine Expression in HIV-1 Encephalitis: Roles for Macrophage Recruitment and Neuroprotection in the Central Nervous System1 (2000) (203)
HHV8-encoded vMIP-I Selectively Engages Chemokine Receptor CCR8 (1999) (201)
Local expression of inflammatory cytokines in human atherosclerotic plaques. (1994) (188)
Fractalkine, a CX3C chemokine, is expressed by dendritic cells and is up‐regulated upon dendritic cell maturation (1999) (188)
Cytomegalovirus-encoded beta chemokine promotes monocyte-associated viremia in the host. (1999) (184)
RANTES, a monocyte and T lymphocyte chemotactic cytokine releases histamine from human basophils. (1992) (182)
Evidence for NK Cell Subsets Based on Chemokine Receptor Expression1 (2006) (178)
CC chemokines induce the generation of killer cells from CD56+ cells (1996) (171)
Chemokine/chemokine receptor nomenclature. (2002) (171)
Proteolytic Activation of Alternative CCR1 Ligands in Inflammation1 (2005) (169)
RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. (1996) (166)
RANTES induces tyrosine kinase activity of stably complexed p125FAK and ZAP-70 in human T cells (1996) (162)
Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)‐1β production by synovial T cells (1995) (157)
CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas (2019) (156)
Functional and biochemical analysis of the cloned Duffy antigen: identity with the red blood cell chemokine receptor. (1994) (152)
Mutations in the erythrocyte chemokine receptor (Duffy) gene: the molecular basis of the Fya/Fyb antigens and identification of a deletion in the Duffy gene of an apparently healthy individual with the Fy(a – b–) phenotype (1995) (150)
Functional Analysis of the Human Cytomegalovirus US28 Gene by Insertion Mutagenesis with the Green Fluorescent Protein Gene (1998) (150)
Proton NMR assignments and solution conformation of RANTES, a chemokine of the C-C type. (1995) (139)
Glucocorticoid inhibition of RANTES expression in human lung epithelial cells. (1995) (136)
Characterization of the human basophil response to cytokines, growth factors, and histamine releasing factors of the intercrine/chemokine family. (1993) (135)
Avacopan for the Treatment of ANCA-Associated Vasculitis. (2021) (133)
Characterization of CCX282-B, an Orally Bioavailable Antagonist of the CCR9 Chemokine Receptor, for Treatment of Inflammatory Bowel Disease (2010) (132)
Chemokine Class Differences in Binding to the Duffy Antigen-Erythrocyte Chemokine Receptor (*) (1995) (131)
The isolation and sequence of a novel gene from a human functional T cell line (1987) (131)
Functional and biochemical analysis of the cloned Duffy antigen: identity with the red blood cell chemokine receptor (1994) (129)
A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn’s Disease (2013) (123)
CXCR4 and CCR5 expression delineates targets for HIV-1 disruption of T cell differentiation. (1998) (121)
Neuronal expression of fractalkine in the presence and absence of inflammation (1998) (110)
Detection of the chemokine RANTES and endothelial adhesion molecules in nasal polyps. (1996) (106)
The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells (2011) (101)
Uncoupling of early signal transduction events from effector function in human peripheral blood neutrophils in response to recombinant macrophage inflammatory proteins-1 alpha and -1 beta. (1993) (99)
Upregulation of RANTES in psoriatic keratinocytes: a possible pathogenic mechanism for psoriasis. (1999) (98)
Engagement of major histocompatibility complex class II molecules by superantigen induces inflammatory cytokine gene expression in human rheumatoid fibroblast-like synoviocytes (1992) (97)
Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study (2016) (97)
The human erythrocyte inflammatory peptide (chemokine) receptor. Biochemical characterization, solubilization, and development of a binding assay for the soluble receptor. (1993) (92)
Primary sensory neurons migrate in response to the chemokine RANTES (1998) (90)
Integrin receptors and RGD sequences in human keratinocyte migration: unique anti-migratory function of alpha 3 beta 1 epiligrin receptor. (1992) (90)
Chemokines as mediators of allergic inflammation. (1996) (86)
CXCR7 Protein Is Not Expressed on Human or Mouse Leukocytes (2010) (85)
Endothelial expression of CXCR7 and the regulation of systemic CXCL12 levels (2014) (84)
RANTES stimulation of T lymphocyte adhesion and activation: role for LFA‐1 and ICAM‐3 (1997) (83)
Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3. (2007) (81)
Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial (2012) (79)
Comprehensive Mapping of Poxvirus vCCI Chemokine-binding Protein (2002) (78)
CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice. (2013) (76)
Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats (2014) (73)
Structural basis of ligand interaction with atypical chemokine receptor 3 (2017) (73)
Cancer associated fibroblast FAK regulates malignant cell metabolism (2020) (72)
CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease. (2012) (70)
Molecular cloning and expression of the murine RANTES cytokine: structural and functional conservation between mouse and man (1992) (68)
Macrophage inflammatory protein-1beta induces migration and activation of human thymocytes. (1998) (66)
Synergistic effect of interleukin-1 beta and tumor necrosis factor alpha on interleukin-8 gene expression in synovial fibroblasts. Evidence that interleukin-8 is the major neutrophil-activating chemokine released in response to monokine activation. (1993) (65)
Fractalkine--a strange attractor in the chemokine landscape. (1997) (64)
Production of monocyte chemotactic protein–1 in human type B synoviocytes. synergistic effect of tumor necrosis factor α and interferon-γ (1993) (63)
Activation of CXCR7 Limits Atherosclerosis and Improves Hyperlipidemia by Increasing Cholesterol Uptake in Adipose Tissue (2014) (63)
RANTES-induced T cell activation correlates with CD3 expression. (1998) (63)
IL‐1 activation of endothelium supports VLA‐4 (CD49d/CD29)‐mediated monocyte transendothelial migration to C5a, MIP‐1α, RANTES, and PAF but inhibits migration to MCP‐1: a regulatory role for endothelium‐derived MCP‐1 (1995) (60)
IL-8-induced signal transduction in T lymphocytes involves receptor-mediated activation of phospholipases C and D. (1995) (59)
Molecular cloning and functional characterization of a novel member of the C-C chemokine family. (1995) (58)
RANTES activation of phospholipase D in Jurkat T cells: requirement of GTP-binding proteins ARF and RhoA. (1998) (58)
Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: Correlation with blood monocyte counts. (2018) (58)
Differential coupling of CC chemokine receptors to multiple heterotrimeric G proteins in human interleukin-2-activated natural killer cells. (1996) (58)
Chemokine Receptor CCR3 Function Is Highly Dependent on Local pH and Ionic Strength* (1997) (52)
Uncoupling of cytokine mRNA expression and protein secretion during the induction phase of T cell anergy. (1992) (51)
Characterization of the Rhesus Cytomegalovirus US28 Locus (2003) (50)
Overexpression of RANTES using a recombinant adenovirus vector induces the tissue-directed recruitment of monocytes to the lung. (1996) (50)
Biologic activities of the murine beta-chemokine TCA3. (1994) (50)
Early pancreatic cancer lesions suppress pain through CXCL12-mediated chemoattraction of Schwann cells (2016) (49)
Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes. (2013) (49)
Corticosteroid inhibition of macrophage inflammatory protein-1 alpha in human monocytes and alveolar macrophages. (1995) (48)
Human keratinocyte migration on type IV collagen. Roles of heparin-binding site and alpha 2 beta 1 integrin. (1994) (45)
The chemokine receptor CXCR7 is expressed on lymphatic endothelial cells during renal allograft rejection. (2010) (40)
CC chemokine receptor 2 promotes recruitment of myeloid cells associated with insulin resistance in nonalcoholic fatty liver disease. (2018) (40)
Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2020) (39)
Induction of chemokine gene expression by major histocompatibility complex class II ligands in human fibroblast-like synoviocytes. Differential regulation by interleukin-4 and dexamethasone. (1994) (39)
IL-17–Secreting γδ T Cells Are Completely Dependent upon CCR6 for Homing to Inflamed Skin (2017) (38)
Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration‐resistant prostate cancer models (2018) (38)
Pathogenic role of CXCR7 in rheumatoid arthritis. (2010) (37)
Human Macrophage Inflammatory Protein cr ( MIP-lc ~ ) and MIPI ~ Chemoklnes Attract Distinct Populations of Lymphocytes (2003) (36)
Abduction of Chemokine Elements by Herpesviruses (1998) (34)
Nonspecific CXCR7 antibodies. (2010) (33)
Human thymocytes express CCR-3 and are activated by eotaxin. (1999) (32)
CCR 6 , a CC Chemokine Receptor that Interacts with Macrophage Inflammatory Protein 3 a and Is Highly Expressed in Human Dendritic Cells (1997) (32)
Cancer Burden Is Controlled by Mural Cell-β3-Integrin Regulated Crosstalk with Tumor Cells (2020) (32)
Proinflammatory Proteases Liberate a Discrete High-Affinity Functional FPRL1 (CCR12) Ligand from CCL2312 (2007) (32)
Chemokines and myeloid cell recruitment. (2000) (31)
Molecular Cloning and Functional Characterization of Human MIP-1δ, a New C–C Chemokine Related to Mouse CCF-18 and C10 (1998) (29)
Abrogation of CC chemokine receptor 9 ameliorates collagen-induced arthritis of mice (2014) (28)
Optimization of 2-aminothiazole derivatives as CCR4 antagonists. (2006) (27)
Orally-Administered Chemokine Receptor CCR2 Antagonist CCX140-B in Type 2 Diabetes: A Pilot Double-Blind, Randomized Clinical Trial (2012) (27)
Chemokine expression in rheumatoid arthritis (1994) (25)
Orally administered CCR2 selective inhibitor CCX872-b clinical trial in pancreatic cancer. (2017) (22)
Expression of human CXCR2 in murine neutrophils as a model for assessing cytomegalovirus chemokine vCXCL-1 function in vivo. (2004) (22)
Production of monocyte chemotactic protein-1 in human type B synoviocytes. Synergistic effect of tumor necrosis factor alpha and interferon-gamma. (1993) (21)
392 PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's Disease (2009) (20)
Efficacy of Chemokine Receptor Inhibition in Treating IL-36α–Induced Psoriasiform Inflammation (2019) (18)
CCR9 Antagonists in the Treatment of Ulcerative Colitis (2015) (17)
Regulation of cytokine and chemokine transcription in a human TH2 type T‐cell clone during the induction phase of anergy (1996) (16)
A Systemically-Administered Small Molecule Antagonist of CCR9 Acts as a Tissue-Selective Inhibitor of Lymphocyte Trafficking (2012) (16)
OP0227 Oral C5a Receptor Antagonist CCX168 Phase 2 Clinical TRIAL in Anca-Associated Renal Vasculitis (2014) (14)
647 Chemokine Receptor Antagonist CCX282-B (Traficet-En™) Maintained Remission of Crohn's Disease in PROTECT-1 Study (2010) (14)
Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory & clinical activity in the treatment of Crohn's disease (2007) (14)
Combination therapy of chemokine receptor inhibition plus PDL-1 blockade potentiates anti-tumor effects in a murine model of breast cancer (2015) (13)
CCR2-Mediated Uptake of Constitutively Produced CCL2: A Mechanism for Regulating Chemokine Levels in the Blood (2019) (13)
CCR 2 antagonist CCX 140-B provides renal and glycemic benefits in diabetic transgenic human CCR 2 knockin mice (2013) (11)
Chemokines of the α, β-subclass inhibit human basophils' responsiveness to monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 (1995) (10)
TO012C5A RECEPTOR INHIBITOR AVACOPAN IN IGA NEPHROPATHY STUDY (2017) (10)
CCR2 antagonism leads to marked reduction in proteinuria and glomerular injury in murine models of focal segmental glomerulosclerosis (FSGS) (2018) (10)
Abstract A107: Inhibition of CCR2 potentiates the checkpoint inhibitor immunotherapy in pancreatic cancer (2016) (10)
Characterization of CCX140-B, an orally bioavailable antagonist of the CCR2 chemokine receptor, for the treatment of type 2 diabetes and associated complications. (2012) (10)
Fractalkine Expression in the Rhesus Monkey Brain During Lentivirus Infection and Its Control by 6-Chloro-2',3'-Dideoxyguanosine (2006) (9)
CCR9 inhibition does not interfere with the development of immune tolerance to oral antigens. (2013) (9)
Protect-1, a prospective randomized oral therapy evaluation of CCX282-B (Traficet-EN) in Crohn's disease trial (2008) (8)
Structures of atypical chemokine receptor 3 reveal the basis for its promiscuity and signaling bias (2022) (8)
CCR 1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease * (2012) (8)
Cc chemokine receptor 9 (ccr9) antagonist ameliorates experimental ileitis and colitis (2005) (8)
Therapeutic use of a clinical stage CCR2 inhibitor, CCX872, in obesity-associated steatohepatitis (2014) (8)
CXCR7 protein expression correlates with elevated mmp-3 secretion in breast cancer cells. (2010) (7)
Abstract 5655: Inhibition of CCR2 potentiates checkpoint inhibitor immunotherapy in murine model of pancreatic cancer (2017) (7)
Receptor/ligand interactions in the C-C chemokine family. (1993) (7)
Tissue proteases convert CCL23 into potent monocyte chemoattractants in patients with chronic rhinosinusitis. (2016) (7)
A small molecule human PD-1/PD-L1 inhibitor promotes T cell immune activation and reduces tumor growth in a preclinical model (2018) (6)
Phase 2 randomised trial of oral C5A receptor antagonist CCX168 in ANCA-associated renal vasculitis (2014) (6)
Expression of the Chemokine Rantes In Human Epithelial-cells (1994) (6)
PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohnʼs Disease: P-0022. (2009) (6)
MO039SUCCESSFUL STEROID REPLACEMENT IN ANCA-ASSOCIATED VASCULITIS WITH C5A RECEPTOR INHIBITOR CCX168 IN PHASE 2 RANDOMISED TRIAL (CLEAR) (2016) (5)
OP0011 A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF AVACOPAN IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)-ASSOCIATED VASCULITIS (2020) (5)
CCR1 Blockade by An Orally-Available CCR1 Antagonist Reduces Tumor Burden and Osteolysis In Vivo In a Mouse Model of Myeloma Bone Disease (2010) (5)
Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study (2019) (4)
Chemokine/Chemokine Receptor Nomenclature∗ (2001) (3)
FRI0002 Inhibition of chemokine receptors ccr1 and ccr6 as promising therapies for rheumatoid arthritis (2013) (3)
C5aR inhibitor on leukocytes exploratory ANCA associated renal vasculitis (CLEAR) clinical trial with orally administered CCX168 (2013) (3)
LB791 Avacopan, a highly selective small molecule inhibitor of c5a receptor, in patients with Hidradenitis Suppurativa: Initial results from a randomized, double-blind, placebo-controlled, phase 2 study (aurora) (2021) (3)
CXCR 7 Ligands Tumor Cell Transendothelial Migration by Events and Inhibition of CXCR 4-Mediated Elucidation of CXCR 7-Mediated Signaling (2009) (3)
CCR 9 Antagonists in the Treatment of Ulcerative Colitis (2015) (3)
LB003A RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED STUDY OF AVACOPAN IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS (2020) (2)
EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY (2013) (2)
OP0046 Effect of a selective c5ar antagonist, avacopan (CCX168), on plasma complement levels in anca associated vasculitis (AAV) (2018) (2)
The inhibition of CCR2 to modify the microenvironment in pancreatic cancer mouse model and to support the profiling of the CCR2 inhibitor CCX872-B in patients. (2016) (2)
POS-112 EFFECT OF AVACOPAN, A SELECTIVE C5A RECEPTOR INHIBITOR, ON COMPLEMENT 3 GLOMERULOPATHY HISTOLOGIC INDEX OF DISEASE CHRONICITY (2022) (2)
Traficet-EN, an Oral CCR9-Specific Antagonist, Induces High Levels of Remission in the Open-Label Phase of PROTECT-1 in Crohnʼs Disease: 1047 (2008) (2)
Reduction of Liver Fibrosis by CCR2 Antagonist CCX872 in Murine Models of NASH: 920 (2016) (2)
CXCR7 Is Expressed in B Acute Lymphoblastic Leukemia (ALL) Cells and Mediates Their Transendothelial Migration. (2008) (2)
Differences in CXCR7 protein expression on rat versus mouse and human splenic marginal zone B cells. (2013) (2)
A human T cell-specific molecule is a member of a new gene family. 1988. (2009) (2)
Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease (2007) (2)
Phase 2 clinical trial of CCX168, an orally administered C5aR antagonist, in patients with ANCA-associated renal vasculitis (CLEAR) (2013) (2)
Pillars Article: A Human T Cell-Specific Molecule Is a Member of a New Gene Family. J. Immunol . 1988. 141: 1018–1025 (2009) (2)
SP457CCR2 INHIBITOR CCX140 EFFECTIVE IN PHASE 2 CLINICAL TRIAL IN DIABETIC NEPHROPATHY (2015) (2)
Tissue directed recruitment of mononuclear cells to the lung using a recombinant adenovirus expressing murine RANTES (1994) (2)
Interleukin-16 or not? (1996) (2)
521 Chemokine receptor inhibition as a novel therapeutic approach for psoriasis (2016) (2)
CCR9 Inhibition in the treatment of Colonic Inflammation: O-0011. (2009) (2)
Diabetes - basic research (2011) (1)
Recruitment and Neuroprotection in the Encephalitis: Roles for Macrophage Neuronal Fractalkine Expression in HIV-1 (2000) (1)
Potent Immunosuppressive Activities of Cytomegalovirus-Encoded Interleukin-10 (2002) (1)
Abstract 5693: Anti-tumor effect of orally available small molecule PD-L1 inhibitors in a murine model of colon adenocarcinoma (2020) (1)
FP167ADVERSE EVENTS WITH GLUCOCORTICOID STANDARD OF CARE VERSUS AVACOPAN IN ANCA-ASSOCIATED VASCULITIS: OBSERVATIONS FROM THE CLEAR TRIAL (2018) (1)
T1143 A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Testing CCX282-B in the Treatment of Celiac Disease (2008) (1)
Erratum: Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10 (Journal of Virology (2002) 76:3 (1285-1292)) (2002) (1)
669 Chemokine receptor CCR6 antagonist reverses psoriaform dermatitis by preventing accumulation of γδT17 cells in skin (2017) (1)
The CCR4 antagonist CCX6239 for the treatment of allergic airways disease (2013) (1)
Expression of CXCR7, CXCR4, CXCR3 and their chemokine ligands in glioblastoma. (2012) (1)
Bicyclic compounds as inhibitors of the binding of chemokine to US28. (2002) (1)
Abstract B26: Tumor reduction by a small molecule human PD-1/PD-L1 inhibitor in a melanoma/PBMC co-implantation model (2020) (1)
ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap (2016) (1)
Clinical studies in CKD 1-5 (2012) (1)
MEDI 167-Discovery of the highly potent, selective and orally bioavailable CCR9 antagonist CCX282-B (2008) (1)
Traficet-EN, an Oral CCR9-Specific Antagonist, induces high levels of remission in the open-label Phase of PROTECT-1 in Crohn's Disease (2008) (1)
LAB-EXPERIMENTAL (PRE-CLINICAL) THERAPEUTICS AND PHARMACOLOGY (2012) (1)
Relationship of Histamine-Releasing Factors to the Human Intercrine/Chemokine Group of Cytokine-Like Molecules. (1992) (1)
IL36-Mediated Skin Inflammation Requires Signaling Through Chemokine Receptor CCR6. (2018) (1)
Abstract B24: Pharmacokinetic and pharmacodynamic profile of the novel, oral and selective CCR2 inhibitor CCX872-B in a Phase 1B pancreatic cancer trial (2015) (1)
PROTECT-1: A Prospective Randomized Trial of CCX282-B (Traficet-EN), a Novel Oral Therapy Targeting Chemokine Receptor 9 in Crohnʼs Disease: 972 (2007) (1)
IMMU-09. DISRUPTION OF THE CCL2-CCR2 AXIS AUGMENTS THE EFFECTS OF IMMUNE CHECKPOINT INHIBITORS TO SLOW PROGRESSION OF GLIOMAS (2017) (1)
Post-Translational Modification By Serine Proteases Controls The CCL23 Activity In Nasal Polyps Of Chronic Rhinosinusitis (2014) (1)
CHAPTER 48 – Fractalkine (2003) (1)
Preliminary data from an ongoing phase 1 dose-escalation study of CCX559, an orally administered small molecule PD-L1 inhibitor, in patients with advanced solid tumors. (2022) (1)
Inhibitors of the binding of chemokine I-TAC or SDF-1 to the receptor ccxckr2 (2003) (1)
OP0203 Orally-administered CCR1 antagonist CCX354-C in a phase 2 rheumatoid arthritis study (2013) (0)
Anti-tumor effects of a small molecule C-C chemokine receptor 4 inhibitor in mouse tumor models (2018) (0)
P0973ALLOSTERIC C-C CHEMOKINE RECEPTOR TYPE 2 (CCR2) INHIBITION IMPROVES RENAL FUNCTION IN A MURINE MODEL OF DIABETIC NEPHROPATHY (2020) (0)
Pharmacological inhibition of CCR9 is a novel approach in the treatment of inflammatory bowel disease (2007) (0)
SP042CREATION OF MOUSE MODELS OF COMPLEMENT MEDIATED RENAL DISEASE USING CRISPR-CAS9 TO INTRODUCE KNOWN HUMAN FACTOR H MUTATIONS IN HUMAN C5A-RECEPTOR KNOCK-IN MICE (2016) (0)
Contents, Vol. 99, 1992 (1992) (0)
SHIELD 4 Phase 3 Clinical Trial With Orally Administered CCR9 Inhibitor Vercirnon in Crohn’s Disease: 1681 (2014) (0)
University of CC Chemokine Receptor 2 Promotes Recruitment of Myeloid Cells Associated with Insulin Resistance in Non-Alcoholic Fatty Liver Disease (2018) (0)
T Cells: Requirement of GTP-Binding Proteins RANTES Activation of Phospholipase D in Jurkat (2017) (0)
SaO058CCR2 INHIBITION IMPROVES RENAL FUNCTION & NORMALIZES GLOMERULAR STRUCTURE IN FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) MODELS (2018) (0)
P251 THERAPEUTIC USE OF A CLINICAL STAGE CCR2 INHIBITOR, CCX872, IMPROVES OBESITY ASSOCIATED STEATOHEPATITIS IN MICE (2014) (0)
Compositions and methods for the detection and treatment of diseases associated with chemokine receptors (2002) (0)
Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan. (2023) (0)
SP004INHIBITION OF THE C5A RECEPTOR BY CCX168 MARKEDLY REDUCES THE THROMBOGENIC POTENTIAL OF SERUM FROM PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (2015) (0)
FP240CCR2 INHIBITION IMPROVES RENAL FUNCTION IN MURINE MODELS OF CHRONIC KIDNEY DISEASE (2019) (0)
Abstract 564: Combination therapy of chemokine receptor inhibition plus PD-L1 blockade potentiates antitumor effects in a murine model of breast cancer (2016) (0)
Cc ckr-1, a chemokine receptor cc (1993) (0)
Small Molecule Inhibition of Chemokine Receptor ‘CCR9’ Combined With Anti-α4β7 Blocking Antibody Confers Synergistic Protection Against Piroxicam-Accelerated Colitis in Mice: 1771 (2014) (0)
The effect of the CXCR7 inhibitor CCX662 on survival in the ENU rat model of glioblastoma. (2012) (0)
OP0204 Characterization of the novel C5AR antagonist CCX168, a potential therapeutic for ANCA-vasculitis, rheumatoid arthritis, and other autoimmune disorders (2013) (0)
Pharmacological inhibition of gut homing CCR9 T-cells alters disease severity in murine models of inflammatory bowel disease: O-0007 (2007) (0)
CCR6, a CC Chemokine Receptor that Interacts with Macrophage Inﬂammatory Protein 3 (cid:97) and Is Highly Expressed in Human Dendritic Cells (1997) (0)
Chemokines of the alpha, beta-subclass inhibit human basophils' responsiveness to monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. (1995) (0)
Orally Administered CCR9 Inhibitor CCX507 Effectively Blocks CCR9 in Circulating Human Leukocytes: 1678 (2014) (0)
FC 032THE EFFECT OF AVACOPAN, A COMPLEMENT C5A RECEPTOR INHIBITOR, ON KIDNEY FUNCTION IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS WITH RENAL DISEASE (2021) (0)
In Vivo Studies of Rantes and the Recruitment of Lymphocytes to Inflammatory Sites (1993) (0)
Abstract 17007: CCR2 Antagonist Inhibits Neointimal Proliferation Post CoronaryStent Deployment (2010) (0)
Differentiation Targets for HIV-1 Disruption of T Cell CXCR4 and CCR5 Expression Delineates (1998) (0)
CX 3 C chemokine genes of mammals (1997) (0)
enhancingtheirantitumorcapacities.Theseresultspointouttheinterestofcordbloodasasourceofcellsforadoptivecancerimmunotherapyusingreceptor-engineeredTcells. the in Reducing and increasing long (2017) (0)
Abstract 1745: Inhibition of chemokine receptor 2 (CCR2) with a small molecule antagonist enhances the effectiveness of checkpoint inhibition by altering the tumor microenvironment in mouse colorectal tumors: Reducing tumor size and increasing long term survival (2018) (0)
Seven structures of atypical chemokine receptor 3 reveal the molecular bases for its promiscuity and signaling bias (2022) (0)
TECK Cell-and T Cell-Active Chemokines Chemokine Receptor That Binds Dendritic Cutting Edge : Identification of a Novel (2000) (0)
Tu1955 Pharmacological Inhibition of C-C Chemokine Receptor 9 (CCR9) Does Not Inhibit the Generation of Oral Tolerance (2012) (0)
TO041CCR2 ANTAGONISM REDUCES PROTEINURIA AND GLOMERULAR INJURY IN MURINE MODELS OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) (2017) (0)
Antagonists of chemokine receptor CCR9 synergize with anti-TNFα immunotherapy to reduce inflammation in the MDR1a−/− mouse model of colitis (2020) (0)
IMMU-05. DISRUPTION OF THE CCR2 CHEMOKINE RECEPTOR PATHWAY OVERCOMES THERAPEUTIC RESISTANCE TO PD-1 BLOCKADE IN MALIGNANT GLIOMA (2019) (0)
FP017Critical Equilibrium between CCL2 Secretion and Its Constitutive Re-Uptake by CCR2: An Elegant Mechanism for Regulating CCL2 Levels in the Blood (2019) (0)
Compositions and methods for the detection and treatment of diseases and conditions related to chemokine receptors (2002) (0)
RANTES and Macrophage Inflammatory Protein lot Induce the Migration and Activation of Normal Human Eosinophil Granulocytes By Antal Rot,* (2003) (0)
691 Neutrophil and C5aR dynamics in hidradenitis suppurativa disease progression (2021) (0)
Abstract 1274: CCX559 is a potent orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity (2021) (0)
or Mouse Leukocytes CXCR7 Protein Is Not Expressed on Human (2010) (0)
P032 Genetic deletion and pharmacological inhibition of chemokine receptor 9 (CCR9) result in opposite effects on the development of oral tolerance (2012) (0)
CX 3 C chemokine genes mammalian cells. (1997) (0)
Tissue proteases convert CCL23 into potent monocyte chemoattractants in chronic rhinosinusitis (2016) (0)
IMST-15. PHARMACOLOGICAL ANTAGONISM OF CCR2 IMPACTS PROGRESSION OF MURINE GLIOMAS (2016) (0)
Fractalkine, a novel CX3C chemokine, is expressed by epidermal melanocytes and langerhans cells (1998) (0)
CC CKR-1 chemokine receptor (1993) (0)
326. A RANDOMIZED PHASE 3 TRIAL EVALUATING THE SAFETY AND EFFICACY OF AVACOPAN IN PATIENTS WITH NEW OR RELAPSING ANCA-ASSOCIATED VASCULITIS (2019) (0)
499 The small molecule PD-L1 inhibitor CCX559 preferentially accumulates in tumors, resulting in depletion of cell-surface PD-L1 in a murine preclinical model (2022) (0)
Latency and myeloid cells (1999) (0)
Inhibition of CCR9 as a therapeutic approach: beyond the small intestine: P‐072. (2008) (0)
P0336INHIBITION C-C CHEMOKINE RECEPTOR TYPE 2 (CCR2) ON ACTIVATED KIDNEY PARIETAL EPITHELIAL CELLS REVEALS A NEW THERAPEUTIC APPROACH FOR CHRONIC KIDNEY DISEASES (2020) (0)
Efficacy of Oral C5aR Inhibitor CCX168 on Non-Renal Disease Activity in Patients withAntineutrophil Cytoplasmic Antibody-Associated Vasculitis (2014) (0)
POS-375 AVACOPAN IN ANCA-ASSOCIATED VASCULITIS: EVIDENCE FOR ELIMINATION OF DAILY PREDNISONE THERAPY AND REDUCTION IN GLUCOCORTICOID-RELATED TOXICITY FROM THE PHASE 3 ADVOCATE TRIAL (2021) (0)
Cancer associated fibroblast FAK regulates malignant cell metabolism (2020) (0)
Cloning and characterization of a novel chemokine-like cytokine (1994) (0)
Tu1499 Efficacy of a Small Molecule CCR2 Antagonist in Experimental Model of Chronic Pancreatitis (2016) (0)
Methods and compositions suitable for inducing an immune response (2002) (0)
W51 THE CXCR7 LIGAND CCX771 REDUCES NEOINTIMA FORMATION AFTER VASCULAR INJURY AND ATHEROSCLEROSIS IN ApoE−/− MICE (2010) (0)
Antibodies that bind to CCX-CKR2 (2006) (0)
Abstract CT223: CCX872: Pharmacodynamic study of a potent and selective CCR2 antagonist in human volunteers and plans for phase Ib trial in patients with pancreatic cancer (2015) (0)
70PChemokine receptor 2 (CCR2) antagonism with a small molecule enhances the effectiveness of checkpoint inhibition by altering the tumor microenvironment in mouse colorectal tumours: Reducing tumor size and increasing long term survival (2017) (0)
IMMU-51. THE COMBINATION OF CCR2 ANTAGONIST AND PD-1 BLOCKADE PROLONGS SURVIVAL IN IMMUNE CHECKPOINT INHIBITOR RESISTANT GLIOMAS (2018) (0)
MO253A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE-RANGING STUDY (LUMINA-1 STUDY) TO EVALUATE THE SAFETY AND EFFICACY OF CCX140 IN SUBJECTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROISS (FSGS)* (2021) (0)
Post-Translational Modification of CCL23 in Chronic Rhinosinusitis with Nasal Polyps (2013) (0)
CCR2 Inhibition Reduces Tumor‐Associated Myeloid‐Derived Suppressor Cells and Unmasks an α‐PD‐1 Effect to Slow Tumor Progression in Checkpoint Inhibitor Resistant Gliomas (2019) (0)
Tu1652 CCX507, an Orally Bioavailable Antagonist of the Chemokine Receptor CCR9, for the Treatment of IBD (2013) (0)
P037 Antagonism of chemokine receptor CCR9 synergises with anti-TNFα immunotherapy to reduce inflammation in the MDR1a−/− mouse model of colitis (2020) (0)
CR 9 inhibition does not interfere with the development of immune tolerance to ral antigens (2013) (0)
Abstract B08: C-C chemokine receptor 4 (CCR4) antagonism enhances the effectiveness of checkpoint Inhibition in mouse tumor models (2020) (0)
725 Targeting chemokine receptors CCR6 and CXCR2 in a murine model of IL-36α-induced pustular psoriasis. (2019) (0)
Focus Session 15: Chemokine Antagonists (2014) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Thomas J. Schall?

Thomas J. Schall is affiliated with the following schools:

Thomas J. Schall's Academic­Influence.com Rankings

Thomas J. Schall's Degrees

Why Is Thomas J. Schall Influential?

Thomas J. Schall's Published Works

Published Works

What Schools Are Affiliated With Thomas J. Schall?

Thomas J. Schall's AcademicInfluence.com Rankings